Drug Profile
PF 06936308
Alternative Names: PF-06936308; Vaccine-based immunotherapy regimen-2; VBIR-2Latest Information Update: 18 Nov 2021
Price :
$50
*
At a glance
- Originator Pfizer
- Class Antineoplastics; Cancer vaccines; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Non-small cell lung cancer; Triple negative breast cancer
Most Recent Events
- 27 Sep 2021 Pfizer terminates a phase I trial in Non-small cell lung cancer and Breast cancer in USA (NCT03674827)
- 28 Jul 2021 Discontinued - Phase-I for Non-small cell lung cancer (Late-stage disease) in USA (Parenteral) (Pfizer pipeline, July 2021)
- 28 Jul 2021 Discontinued - Phase-I for Triple negative Breast cancer (Late-stage disease) in USA (Parenteral) (Pfizer pipeline, July 2021)